Top Markets
#1 Black Phoenix Black Phoenix +367.29%
#2 Islamic Coin Islamic Coin +158.24%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +55.02%
#5 Akedo Akedo +53.30%
#6 Acurast Acurast +37.40%
#7 BasedHype BasedHype +30.34%
#8 Cryptopia Cryptopia +22.42%
#9 Avantis Avantis +21.94%
#10 Playnance Playnance +19.70%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Nunzia Pharmaceutical Company Nunzia Pharmaceutical Company

Nunzia Pharmaceutical Company

NUNZ
株式のランク #41102
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical... Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.
株価
$0.0001
最終同期: 2026-08-12
時価総額
$43.45K
変化（1日）
0.00%
変化（1年）
-96.67%
国
US
取引 Nunzia Pharmaceutical Company (NUNZ)

カテゴリー

Healthcare
Nunzia Pharmaceutical Company（NUNZ）の収益
Aug 2026 時点の収益 TTM: 0
Nunzia Pharmaceutical Company の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Nunzia Pharmaceutical Company の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US